J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €100.00.

Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as ...

Bank of America Securities analyst Graham Parry maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target ...

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on ...

September 26, 2024. Sanofi announced today that its Q3 2024 Aide mémoire is available on the "Investors" page of the company's website: Third quarter 2024 results (sanofi.com) As for each quarter, ...

Shares of Sanofi fell about 0.8% in early Wednesday trading in Paris, giving the drugmaker a market value of about €130.5 ...

EADV: New data reinforce Sanofi’s innovative approach and leadership across immune-mediated skin diseases 24 abstracts for Dupixent, including 4 oral presentations, highlight impact of ...

Paul Hudson Chief Executive Officer at Sanofi "Dupixent has already shown it can revolutionize the treatment paradigm of many diseases driven in part by type 2 inflammation with high unmet medical ...

Several French companies have committed to making new investments in the Egyptian market across various sectors, including ...

IMTOZ trial findings and subsequent approval of Isa-VRd regimen for transplant-ineligible myeloma suggested the combo as a ...

The Paris case was brought by Marine Martin whose ... interventions and was also diagnosed with Asperger's autism. Sanofi was ordered to pay €280,000 (£236,539) and Mdm Martin's victory could ...

The Paris Olympics have been a showcase not only for athletic ... of using the Olympics to sell products of dubious medical value. French pharmaceutical giant Sanofi came under criticism for promoting ...